3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Cholangiocarcinoma
1
Carcinoma, Ovarian Epithelial
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
9
Gemcitabine
5
Cisplatin
5
Nivolumab
3
Drug Therapy
3
budigalimab
2
Paclitaxel
2
Injections
2
Docetaxel
2
Carboplatin
2
zenocutuzumab
1
venetoclax
1
tislelizumab
1
spartalizumab
1
seribantumab
1
saracatinib
1
rovalpituzumab tesirine
1
pertuzumab
1
pemigatinib
1
niraparib
1
nilotinib
1
margetuximab
1
lenvatinib
1
futibatinib
1
fludarabine
1
entrectinib
1
durvalumab
1
crenigacestat
1
cediranib
1
bemarituzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
bemarituzumab
×
Breast
×
Clear all
NCT05325866
2026-02-04
FORTITUDE-301
Amgen
Phase 1/2
Completed
260 enrolled